Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Milestone Scientific (MLSS) Current Deferred Revenue (2016 - 2021)

Historic Current Deferred Revenue for Milestone Scientific (MLSS) over the last 7 years, with Q3 2021 value amounting to $407050.0.

  • Milestone Scientific's Current Deferred Revenue rose 1955.32% to $407050.0 in Q3 2021 from the same period last year, while for Sep 2021 it was $407050.0, marking a year-over-year increase of 1955.32%. This contributed to the annual value of $242589.0 for FY2020, which is 2875.0% down from last year.
  • Per Milestone Scientific's latest filing, its Current Deferred Revenue stood at $407050.0 for Q3 2021, which was up 1955.32% from $337145.0 recorded in Q2 2021.
  • Milestone Scientific's Current Deferred Revenue's 5-year high stood at $2.8 million during Q2 2018, with a 5-year trough of $241288.0 in Q1 2021.
  • In the last 5 years, Milestone Scientific's Current Deferred Revenue had a median value of $372700.0 in 2019 and averaged $707660.8.
  • As far as peak fluctuations go, Milestone Scientific's Current Deferred Revenue soared by 38413.3% in 2018, and later tumbled by 8677.43% in 2019.
  • Over the past 5 years, Milestone Scientific's Current Deferred Revenue (Quarter) stood at $1.7 million in 2017, then tumbled by 75.55% to $421800.0 in 2018, then decreased by 19.28% to $340476.0 in 2019, then decreased by 28.75% to $242589.0 in 2020, then skyrocketed by 67.79% to $407050.0 in 2021.
  • Its Current Deferred Revenue stands at $407050.0 for Q3 2021, versus $337145.0 for Q2 2021 and $241288.0 for Q1 2021.